Cargando…

HIF2α Activation in NASH: A New Force Pushing Toward HCC

Detalles Bibliográficos
Autores principales:	Clavería-Cabello, Alex, Avila, Matías A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777000/ https://www.ncbi.nlm.nih.gov/pubmed/34848185 http://dx.doi.org/10.1016/j.jcmgh.2021.11.005

Ejemplares similares

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
por: Yu, Simiao, et al.
Publicado: (2022)

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
por: Pfister, Dominik, et al.
Publicado: (2021)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
por: Shao, Gaoxuan, et al.
Publicado: (2022)

Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
por: Boslem, Ebru, et al.
Publicado: (2023)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression
por: Yamada, Kohei, et al.
Publicado: (2023)

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
por: De Minicis, Samuele, et al.
Publicado: (2014)

Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
por: Grohmann, Marcus, et al.
Publicado: (2018)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
por: Ge, Chenxu, et al.
Publicado: (2022)

NRF2 Induction for NASH Treatment: A New Hope Rises
por: Rojo de la Vega, Montserrat, et al.
Publicado: (2018)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation
por: Foglia, Beatrice, et al.
Publicado: (2021)

Pushing the Envelope
por: Wojtys, Edward M.
Publicado: (2016)

NASH: Connecting the dots with patients in mind
por: Cryer, Donna R.
Publicado: (2020)

Something to mTORC About in NASH
por: Finck, Brian N.
Publicado: (2022)

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2022)

Erratum for the Research Article: “Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC”
Publicado: (2023)

Unraveling the molecular links between benzopyrene exposure, NASH, and HCC: an integrated bioinformatics and experimental study
por: Yang, Zheming, et al.
Publicado: (2023)

Letter from Dr. Nash
por: Hart, James A.
Publicado: (1875)

Neurons join forces to push ahead
por: Leslie, Mitch
Publicado: (2015)

Targeting bile acids and lipotoxicity for NASH treatment
por: Chiang, John Y. L.
Publicado: (2017)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

NAFLD as a risk factor for HCC: new rules of engagement?
por: Masuzaki, Ryota, et al.
Publicado: (2016)

Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC
por: Ande, Sudharsana R., et al.
Publicado: (2016)

Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis
por: Huang, Wei, et al.
Publicado: (2017)

Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC
por: Ribas, Vicent, et al.
Publicado: (2021)

Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC
por: Zhang, Yueqi, et al.
Publicado: (2021)

FGF9 Recruits β‐Catenin to Increase Hepatic ECM Synthesis and Promote NASH‐Driven HCC
por: Zhang, Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i2nsse6kvniain5f3nujpitp5m